A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement

AIM: We investigated the efficacy, safety and optimal schedule of nanoparticle albumin‐bound paclitaxel monotherapy as second‐ or third‐line treatment for non‐small‐cell lung cancer patients without epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement. METHODS: Pati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Asia Pac J Clin Oncol
Autors principals: Harada, Daijiro, Kozuki, Toshiyuki, Nogami, Naoyuki, Bessho, Akihiro, Hosokawa, Shinobu, Fukamatsu, Nobuaki, Hotta, Katsuyuki, Ohashi, Kadoaki, Kubo, Toshio, Yoshioka, Hiroshige, Yokoyama, Toshihide, Sone, Naoyuki, Kuyama, Shoichi, Kudo, Kenichiro, Yasugi, Masayuki, Takigawa, Nagio, Oze, Isao, Kiura, Katsuyuki
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849786/
https://ncbi.nlm.nih.gov/pubmed/30938103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13147
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars